

**Table 1. Primary outcome from the NADINA study**

	<b>Neoadjuvant group (n = 212)</b>	<b>Adjuvant group (n = 211)</b>
<b>Number of events</b>	28	72
<b>Estimated 12-month EFS</b>	83.7% (99.9% CI, 73.8 to 94.8)	57.2% (99.9% CI, 45.1 to 72.7)
<b>Adjusted difference in restricted mean survival time</b>	8.00 months (99.9% CI, 4.94 to 11.05; p < 0.001)	
<b>Hazard ratio for progression, recurrence, or death</b>	0.32; (99.9% CI, 0.15 to 0.66)	
EFS: event-free survival; CI: confidence interval		